Download PDF
Klin Padiatr 2013; 225(07): 398-404
DOI: 10.1055/s-0033-1358749
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Disposition of Midazolam in Asphyxiated Neonates Receiving Therapeutic Hypothermia – A Pilot Study

Metabolismus von Midazolam bei therapeutischer Hypothermie von asphyktischen Neugeborenen – eine Pilotstudie
L. Welzing   *
1   Childrens Hospital, Department of Neonatology, University of Bonn, Germany
,
S. Junghaenel   *
2   Department of Neonatology and Paediatric Intensive Care, Children’s Hospital, University of Cologne, Germany
,
V. Weiss
3   Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Germany
,
B. Roth
2   Department of Neonatology and Paediatric Intensive Care, Children’s Hospital, University of Cologne, Germany
,
C. Mueller
4   Division of Therapeutic Drug Monitoring, Department of Pharmacology, University Hospital of Cologne, Germany
,
M. H. J. Wiesen
4   Division of Therapeutic Drug Monitoring, Department of Pharmacology, University Hospital of Cologne, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

Moderate hypothermia has become an established therapy for asphyxiated neonates. Midazolam is a frequently used sedative for this indication, although it has never been investigated how therapeutic hypothermia and asphyxia influence midazolam metabolism in neonates.

Patients and Methods:

9 asphyxiated newborns were treated with whole body hypothermia of 32–34°C for 72 h and all of them received continuous midazolam infusion for sedation. Serum concentrations of midazolam and its metabolites 1-hydroxy-midazolam and 4-hydroxy-midazolam were measured during hypothermia and the rewarming period. Renal and hepatic parameters were assessed to take into account the influence of asphyxia related renal or hepatic impairment.

Results:

We found a high interindividual variability of serum midazolam concentrations in asphyxiated neonates with therapeutic hypothermia; median midazolam concentration was 369.3 ng/ml (minimum 36.6; maximum 3 218.6 ng/ml). The population pharmacokinetic model revealed a midazolam clearance of 2.57 ml/kg/min, comparable to midazolam clearances observed in normothermic critically ill neonates. However, midazolam clearance was significantly decreased in patients with asphyxia related renal and hepatic impairment.

Conclusion:

It seems that isolated hypothermia does not significantly influence midazolam metabolism. However, neonates with asphyxia related hepatic and renal impairment are at risk of generating unexpectedly high serum midazolam concentrations. In addition pronounced interindividual variability of midazolam metabolism may contribute to dangerously high midazolam concentrations.

Zusammenfassung

Einleitung:

Die moderate Hypothermie ist in den letzten Jahren bei asphyktischen Neugeborenen zu einer etablierten Therapie geworden. Zur Sedierung wird den Kindern dabei häufig Midazolam verabreicht, obwohl es keine Daten darüber gibt, wie sich Hypothermie und Asphyxie bei Neugeborenen auf die Metabolisierung von Midazolam auswirken.

Patienten und Methode:

9 asphyktische Neugeborene wurden über 72 Stunden mit einer therapeutischen Hypothermie von 32–34°C und einer Midazolam-Dauerinfusion therapiert. ­Sowohl in der Hypothermie- als auch in der Aufwärmphase erfolgten regelmäßige Messungen der Serumkonzentration von Midazolam und seinen Metaboliten 1-Hydroxy-Midazolam und 4-Hydroxy-Midazolam. Zur Erfassung Asphyxie-bedingter Leber- und Nierenschädigungen wurden zusätzlich Leber- und Nierenparameter ­bestimmt.

Ergebnisse:

Die Midazolam-Serumkonzentrationen wiesen bei den gekühlten, asphyktischen Neugeborenen eine große interindividuelle Streubreite auf; die mittlere Midazolam-Konzentration betrug 369,3 ng/ml (Minimum 36,6; Maximum 3 218,6 ng/ml). Das Populationskinetische Modell ergab, ähnlich wie bei normothermen kranken Neugeborenen, eine Clearance von 2,57 ml/kg/min. Bei den Neugeborenen mit Asphyxie-bedingter Leber- und Nierenschädigung hingegen war die Clearance signifikant erniedrigt.

Schlussfolgerungen:

Die isolierte therapeutische Hypothermie scheint bei Neugeborenen zu keinen signifikanten Veränderungen im Metabolismus von Midazolam zu führen. Bei Neugeborenen mit Asphyxie-bedingter Leber- und Nierenschädigung hingegen können unerwartet hohe Midazolam-Konzentrationen auftreten.

Key words

neonate - asphyxia - midazolam - therapeutic hypothermia - population ­pharmacokinetics

Schlüsselwörter

Neugeborene - Asphyxie - Midazolam - therapeutische ­Hypothermie - Populationskinetik

* L. Welzing and S. Junghaenel both serve as first author as they contributed equally to this work.


 

  • References

  • 1 Anand KS. Relationships between stress responses and clinical outcome in newborns, infants, and children. Crit Care Med 1993; 21: S358-S359
    CrossrefPubMedGoogle Scholar
  • 2 Austin KL, Stapleton JV, Mather LE. Pethidine clearance during continuous intravenous infusions in postoperative patients. Br J Clin Pharmacol 1981; 11: 25-30
    CrossrefPubMedGoogle Scholar
  • 3 Azzopardi D, Brocklehurst P, Edwards D et al. The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: a randomised controlled trial. BMC Pediatr 2008; 8: 17
    CrossrefPubMedGoogle Scholar
  • 4 Azzopardi DV, Strohm B, Edwards AD et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361: 1349-1358
    CrossrefPubMedGoogle Scholar
  • 5 Bastiaans DE, Swart EL, van Akkeren JP et al. Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. Int J Clin Pharm 2013; 35: 210-216
    CrossrefPubMedGoogle Scholar
  • 6 Bjelland TW, Klepstad P, Haugen BO et al. Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. Drug Metab Dispos 2013; 41: 214-223
    CrossrefPubMedGoogle Scholar
  • 7 Burtin P, Jacqz-Aigrain E, Girard P et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615-625
    CrossrefPubMedGoogle Scholar
  • 8 de Loor H, de Jonge H, Verbeke K et al. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1’-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomed Chromatogr 2011; 25: 1091-1098
    CrossrefPubMedGoogle Scholar
  • 9 de Wildt SN, de HM, Vinks AA et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003; 31: 1952-1958
    CrossrefPubMedGoogle Scholar
  • 10 Dostalek M, Macwan JS, Chitnis SD et al. Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1’-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1629-1633
    PubMedGoogle Scholar
  • 11 Eap CB, Bouchoux G, Powell GK et al. Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 339-345
    PubMedGoogle Scholar
  • 12 Hunseler C, Merkt V, Gerloff M et al. Assessing pain in ventilated newborns and infants: validation of the Hartwig score. Eur J Pediatr 2011; 170: 837-843
    CrossrefPubMedGoogle Scholar
  • 13 Jacqz-Aigrain E, Daoud P, Burtin P et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet 1994; 344: 646-650
    CrossrefPubMedGoogle Scholar
  • 14 Jacqz-Aigrain E, Daoud P, Burtin P et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol 1992; 42: 329-332
    PubMedGoogle Scholar
  • 15 Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39: 191-192
    CrossrefPubMedGoogle Scholar
  • 16 Kuhlen M, Schneider K, Richter U et al. Palliative sedation in 2 children with terminal cancer – an effective treatment of last resort in a home care setting. Klin Padiatr 2011; 223: 374-375
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesth Analg 2007; 104: 509-520
    CrossrefPubMedGoogle Scholar
  • 18 Michel-Behnke I, Rothes A, Hund F et al. Analgosedation with Fentanyl/Midazolam Following Corrective Cardiac Surgery of Congenital Heart Defects. Klin Padiatr 1995; 207: 341-346
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276
    CrossrefPubMedGoogle Scholar
  • 20 Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-163
    CrossrefPubMedGoogle Scholar
  • 21 Roka A, Vasarhelyi B, Bodrogi E et al. Changes in laboratory parameters indicating cell necrosis and organ dysfunction in asphyxiated neonates on moderate systemic hypothermia. Acta Paediatr 2007; 96: 1118-1121
    CrossrefPubMedGoogle Scholar
  • 22 Schmidt B, Adelmann C, Stutzer H et al. Comparison of sufentanil versus fentanyl in ventilated term neonates. Klin Padiatr 2010; 222: 62-66
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Shellhaas RA, Ng CM, Dillon CH et al. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 2013; 14: 194-202
    CrossrefPubMedGoogle Scholar
  • 24 Simbruner G, Mittal RA, Rohlmann F et al. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. Pediatrics 2010; 126: e771-e778
    CrossrefPubMedGoogle Scholar
  • 25 Thoresen M, Satas S, Loberg EM et al. Twenty-four hours of mild hypothermia in unsedated newborn pigs starting after a severe global hypoxic-ischemic insult is not neuroprotective. Pediatr Res 2001; 50: 405-411
    CrossrefPubMedGoogle Scholar
  • 26 Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007; 35: 2196-2204
    CrossrefPubMedGoogle Scholar
  • 27 U. S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry on Population Pharmacokinetics. 1999
    PubMedGoogle Scholar
  • 28 van den Broek MP, Groenendaal F, Egberts AC et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010; 49: 277-294
    CrossrefPubMedGoogle Scholar
  • 29 Wang C, Slikker Jr W. Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system. Anesth Analg 2008; 106: 1643-1658
    CrossrefPubMedGoogle Scholar
  • 30 Zanelli S, Buck M, Fairchild K. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J Perinatol 2011; 31: 377-386
    CrossrefPubMedGoogle Scholar